Skip to content

News

The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (“the Company”) on...
The Phase IIa results demonstrated that Sepranolone could become the first-line pharma treatment for Tourette as it showed competitive tic reduction and...
The full Annual Report 2022 is available on: https://asarinapharma.com/investors/financial-reports/ Research and Development: This year, Asarina’s...
NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. Right to participate...
THE STUDY: This was an open label, dual center, add-on study, randomizing 28 Tourette Syndrome patients, 20 males/8 females, 3 adolescents/25 adults between...
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS Recruitment completed: patient recruitment to Phase IIa study in Tourette completed in October 2022. A total of...
A total of 28 patients took part in the study: a ‘control group’ of 9 patients who received their standard treatment, plus an ‘active...
Enrollment of adult patients started at the Bispebjerg University Hospital in Copenhagen in February 2022, while teenage patients have been enrolled at...
A new study, the fourth and most comprehensive in a series of four (1), reconfirms that acute stress increases the overproduction of the powerful neurosteroid...
A new study – ‘Estimating the number of people with Tourette syndrome and persistent tic disorder in the United States’ - has been published...